Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate

Background: Dengue is a rapidly spreading mosquito borne tropical viral disease affecting hundreds of millions of people across the globe annually. The dengue virus (DENV) includes four genetically distinct serotypes that cause serious life-threatening infections, including dengue hemorrhagic fever/dengue shock syndrome. Dengue vaccine development is complicated by the possibility of vaccine-enhanced severe dengue disease due to antibody-dependent enhancement by pre-existing cross-reactivity, as well as homotypic antibodies. Thus, the development of an efficacious dengue vaccine conferring simultaneous and durable immunity to each of the four DENV serotypes has not yet been developed despite years of research. For mass immunization in deeply affected resource-limited countries, oral vaccination is considered more beneficial than conventional approaches. Therefore, in a continuing effort towards designing economical and potent vaccine candidates, the current study applied yeast surface display technology to develop an oral dengue vaccine candidate using whole recombinant yeast cells displaying the recombinant fusion protein of M cell targeting ligand Col fused to the synthetic consensus dengue envelope domain III (scEDIII). Female Balb/c mice were orally fed with recombinant yeast cells and immunogenicity in terms of systemic and mucosal immune responses was monitored. Results: Immunofluorescence microscopy with dengue specific antibody and fluorescein isothiocyanate-conjugated anti-mouse IgG antibody clearly showed that recombinant protein Col -scEDIII-AGA was localized on the cell surface of the respective clones in comparison with scEDIII-Col and Mock cells with no fluorescence. Oral dosage applications of surface displayed Col -scEDIII-AGA stimulated a systemic humoral immune response in the form of denguespecific serum IgG, as well as a mucosal immune response in the form of secretory immunoglobulin A (sIgA). Antigenspecific B cell responses in isolated lymphoid cells from the spleen and Peyer's patches further supported an elevated mucosal immune response. In addition, surface displayed Col -scEDIII-AGA feeding elicited strong immune responses in comparison with scEDIII-Col and Mock following intraperitoneal booster with purified scEDIII antigen. Conclusions: Surface displayed preparations of Col -scEDIII-AGA induced strong immunogenicity compared with non-displayed scEDIII-Col . Prior studies have supported the neutralization potential of scEDIII constructs against all four serotypes. Thus, the oral administration of genetically engineered yeast whole cells displaying biologically active Col-scEDIII fusion protein without any further processing shows prospective as a potent oral vaccine candidate against dengue viral infection.